Assessing risk for HIV infection among adolescent girls in South Africa: an evaluation of the VOICE risk score (HPTN 068).


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
07 2019
Historique:
received: 21 11 2018
accepted: 04 07 2019
entrez: 30 7 2019
pubmed: 30 7 2019
medline: 28 4 2020
Statut: ppublish

Résumé

To maximize impact and minimize costs, antiretroviral pre-exposure prophylaxis (PrEP) interventions should be offered to those at highest risk for HIV infection. The risk score derived from the VOICE trial is one tool currently being utilized to determine eligibility in adolescent PrEP trials in sub-Saharan Africa. This study is aimed at evaluating the utility of the risk score in predicting HIV incidence among a cohort of adolescent girls in rural South Africa. We utilized data from HIV Prevention Trials Network (HPTN) 068, a phase III randomized controlled trial conducted in rural Mpumalanga province, South Africa. School-attending young women aged 13 to 20 years were enrolled into the trial from 2011 to 2012 and followed for up to three years. A risk score based on individual-level risk factors measured at enrolment was calculated for HPTN 068 participants who completed a one-year follow-up visit and were HIV seronegative at enrolment. Possible scores ranged from 0 to 10. A proportional hazards model was then used to determine if risk score at enrolment was predictive of incident HIV infection at follow-up and an area under the curve analysis was used to examine the predictive ability of the score. The risk score had limited variability in the HPTN 068 sample. Scores ≥5 identified 85% of incident infections from 94% of the sample, compared to the VOICE sample in which scores ≥5 identified 91% of incident infections from only 64% of participants. The risk score did not predict HIV incidence after one year of follow-up (hazard ratio = 1.029; 95% confidence interval (CI): 0.704, 1.503, p = .884) and showed poor predictive ability (area under the curve = 0.55; 95% CI: 0.44, 0.65). Certain individual risk factors that comprise the risk score may be context specific or not relevant for adolescent populations. Additional factors should be considered when assessing risk for the purposes of determining PrEP eligibility. The VOICE risk score demonstrated low utility to predict HIV incidence in the HPTN 068 sample. Findings highlight the need for an age and developmentally appropriate tool for assessing risk for HIV infection among adolescents. Use of the VOICE risk score for determining PrEP eligibility in younger populations should be carefully considered.

Identifiants

pubmed: 31353814
doi: 10.1002/jia2.25359
pmc: PMC6661402
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25359

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI069423
Pays : United States
Organisme : NIH HHS
ID : P2CHD050924
Pays : United States
Organisme : NIMH NIH HHS
ID : R01MH087118
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069530
Pays : United States
Organisme : The Eunice Kennedy Shriver National Institute of Child Health and Human Development
ID : UM1AI068619
Pays : International
Organisme : NICHD NIH HHS
ID : P2C HD050924
Pays : United States
Organisme : The Eunice Kennedy Shriver National Institute of Child Health and Human Development
ID : UM1AI068613
Pays : International
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068617
Pays : United States

Informations de copyright

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

AIDS. 2011 Apr 24;25(7):957-66
pubmed: 21330907
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
AIDS Behav. 2016 Sep;20(9):1863-82
pubmed: 26891839
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
AIDS Behav. 2004 Sep;8(3):237-50
pubmed: 15475673
Int J Epidemiol. 2008 Dec;37(6):1266-73
pubmed: 18614609
J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):421-7
pubmed: 22487585
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):155-162
pubmed: 29767637
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):339-47
pubmed: 23187945
J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21107
pubmed: 27760684
J Int AIDS Soc. 2019 Jul;22(7):e25359
pubmed: 31353814
Lancet Glob Health. 2016 Dec;4(12):e978-e988
pubmed: 27815148
Int Fam Plan Perspect. 2006 Dec;32(4):192-200
pubmed: 17237016
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):333-43
pubmed: 26918545
AIDS. 2018 Jul 31;32(12):1669-1677
pubmed: 29762176
Clin Infect Dis. 2013 Apr;56(8):1149-55
pubmed: 23223604
Sex Transm Dis. 2009 Sep;36(9):547-55
pubmed: 19707108
AIDS. 2019 Jan 27;33(1):83-91
pubmed: 30289813
Lancet Glob Health. 2015 Aug;3(8):e470-e477
pubmed: 26134875
Int J Epidemiol. 2012 Aug;41(4):988-1001
pubmed: 22933647
AIDS. 2017 Sep 24;31(15):2127-2134
pubmed: 28692544

Auteurs

Danielle Giovenco (D)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Audrey Pettifor (A)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Catherine MacPhail (C)

School of Health and Society, University of Wollongong, Wollongong, New South Wales, Australia.
MRC/Wits Rural, Public Health and Health Transitions Research Unit (Agincourt), Acornhoek, South Africa.

Kathleen Kahn (K)

MRC/Wits Rural, Public Health and Health Transitions Research Unit (Agincourt), Acornhoek, South Africa.

Ryan Wagner (R)

MRC/Wits Rural, Public Health and Health Transitions Research Unit (Agincourt), Acornhoek, South Africa.

Estelle Piwowar-Manning (E)

Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.

Jing Wang (J)

Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

James P Hughes (JP)

Department of Biostatistics, University of Washington, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH